SCHEMBL6774992

SCHEMBL6774992

C[C@@H]1CCN(CCO)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12717823 1.00
SCHEMBL1430963 1.00
SCHEMBL12449635 0.87 KDM4E (0.51)
SCHEMBL13003 0.87 KDM4E (0.51)
SCHEMBL2115306 0.87 SIGMAR1 (0.41)
SCHEMBL12449637 0.87 KDM4E (0.51)
SCHEMBL14685579 0.87 SIGMAR1 (0.41)
SCHEMBL91689 0.86 CARM1 (0.56)
SCHEMBL21786271 0.84 KDM4E (0.49)
SCHEMBL9374563 0.81 SIGMAR1 (0.46)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3205648-A1 ESTROGEN RECEPTOR MODULATORS AND USES THEREOF Seragon Pharmaceuticals, Inc. (US) 2017-08-16 EP disclosed
EP-3205648-A1 ESTROGEN RECEPTOR MODULATORS AND USES THEREOF Seragon Pharmaceuticals, Inc. (US) 2017-08-16 EP disclosed
EP-2580210-B1 ESTROGEN RECEPTOR MODULATORS AND USES THEREOF SERAGON PHARMACEUTICALS INC (US) 2017-03-01 EP disclosed
EP-2580210-B1 ESTROGEN RECEPTOR MODULATORS AND USES THEREOF SERAGON PHARMACEUTICALS INC (US) 2017-03-01 EP disclosed
CN-102939287-B Estrogenic agents and uses thereof ARAGON PHARMACEUTICALS, INC. (US) 2016-01-27 CN disclosed
US-20150197506-A1 NOVEL BENZOPYRAN COMPOUNDS, COMPOSITIONS AND USES THEREOF OLEMA PHARMACEUTICALS, INC. (US) 2015-07-16 US disclosed
US-20150197506-A1 NOVEL BENZOPYRAN COMPOUNDS, COMPOSITIONS AND USES THEREOF OLEMA PHARMACEUTICALS, INC. (US) 2015-07-16 US disclosed
US-20150197506-A1 NOVEL BENZOPYRAN COMPOUNDS, COMPOSITIONS AND USES THEREOF OLEMA PHARMACEUTICALS, INC. (US) 2015-07-16 US disclosed
US-9078871-B2 Estrogen receptor modulators and uses thereof SERAGON PHARMACEUTICALS, INC. (US) 2015-07-14 US disclosed
US-9078871-B2 Estrogen receptor modulators and uses thereof SERAGON PHARMACEUTICALS, INC. (US) 2015-07-14 US disclosed
US-20130116232-A1 ESTROGEN RECEPTOR MODULATORS AND USES THEREOF ARAGON PHARMACEUTICALS, INC. (US) 2013-05-09 US disclosed
US-20130116232-A1 ESTROGEN RECEPTOR MODULATORS AND USES THEREOF ARAGON PHARMACEUTICALS, INC. (US) 2013-05-09 US disclosed
US-20130116232-A1 ESTROGEN RECEPTOR MODULATORS AND USES THEREOF ARAGON PHARMACEUTICALS, INC. (US) 2013-05-09 US disclosed
CN-102939287-A Estrogen receptor modulators and uses thereof ARAGON PHARMACEUTICALS INC 2013-02-20 CN disclosed
WO-2013018804-A1 URACIL DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES 大日本住友製薬株式会社 (JP) 2013-02-07 WO disclosed
WO-2011156518-A2 ESTROGEN RECEPTOR MODULATORS AND USES THEREOF ARAGON PHARMACEUTICALS, INC. (US) 2011-12-15 WO disclosed
US-6750213-B2 BONE DISORDERS; UROGENITAL SYSTEM DISORDERS; ANTICANCER AGENTS MERCK & CO., INC. 2004-06-15 US disclosed
US-20030225132-A1 Heterocyclic salts such as 3-(3-Hydroxyphenyl)-2-(4-(2-(1-pyrrolidinium)ethoxyphenol)-2,3-dihydro-1,4 -benzoxathiin-6-ol hydrochloride salt, used as estrane agonists, for phrophylaxis of bone disorders DININNO FRANK P (US) 2003-12-04 US disclosed
WO-2003086388-A1 ESTROGEN RECEPTOR MODULATORS MERCK & CO., INC. (US) 2003-10-23 WO disclosed
US-20020165226-A1 Estrogen receptor modulators MERCK & CO., INC. 2002-11-07 US disclosed